Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$1.56
▲ $0.07 (+4.7%)
Market data updated: 09/15 01:37 AM
Fundamentals updated: 09/15/2026
News analyzed: 09/15/2026
Market Cap
$1.16B
Day Range
$1.54 - $1.60
52-Week Range
$0.98 - $1.73
Beta
—
Next Earnings
27.10.2026
OPK is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+9.8% (1Y)
Strengths: 14/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Leverage risk
Debt/equity: 0.27
Risk
Biggest negative driver
Operating margin
Operating margin: -19.3% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
56
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
32
Quality
47
Value
50
Momentum
79
Risk
46
Sentiment
100
Fundamental
36
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Everyone's writing about Opko Health, Inc.. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
32
🎯 Conviction (vs. Emotion)
37
Psychology
92
Fundamentals
36
Technical
79
Valuation
50
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+11%
Market Narrative
70
Fundamental Reality
37
Narrative Gap
+33
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Philip Fisher — 9/100
🗣️ Why do they disagree?
Based on Benjamin Graham’s defensive criteria, the model estimates OPK is highly attractive, reflected by a perfect 100 score and a strong margin of safety, while Walter Bagehot’s liquidity focus also yields a near‑perfect 98, suggesting the company would likely survive a credit squeeze. Graham’s enterprising framework, however, rates the stock lower at 84, indicating a statistical discount but a more modest margin for the more aggressive investor. Jesse Livermore, Gerald Loeb, and Samuel Nelson all signal limited upside or moderate risk, with scores in the 40‑60 range and verdicts describing no clear trend or only mid‑cycle signals. Howard Marks, Morgan Housel, and the efficient‑market view each assign mixed or modest scores (42‑35), highlighting that the business is decent but possibly over‑valued or lacking a strong edge versus an index. Finally, Peter Lynch, Philip Fisher, Thorstein Veblen, and the efficient‑market proponents rate OPK very low (22‑9), concluding that the stock fails to meet their growth‑at‑reasonable‑price, quality, or non‑speculative growth standards.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 98
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 84
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 62
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 52
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 49
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 47
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 44
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 42
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 42
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 38
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 35
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 30
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 23
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 22
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 9
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Based on the last 277 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
33.9%
Operating Margin
-19.3%
Net Margin
-37.2%
EBITDA Margin
-4.2%
ROE
-17.8%
ROA
-11.7%
ROIC
—
EPS
-$0.30
Cash
$364.41M
Total Debt
$346.23M
Current Ratio
3.97
Debt/Equity
0.27
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$1.69
Tangible Book Value per Share (Tangible NAV)
$0.36
Sentiment based on basic keywords (not AI) — 10 positive, 9 neutral, 1 negative out of the last 20 articles.
Yahoo · 14.9.2026
Yahoo · 11.9.2026
Yahoo · 8.9.2026
Yahoo · 4.9.2026
Yahoo · 3.9.2026
Exec Edge · 31.8.2026
Zacks · 26.8.2026
Zacks · 24.8.2026
Zacks Small Cap Research · 20.8.2026
Zacks · 19.8.2026
Zacks · 19.8.2026
Zacks · 19.8.2026
Zacks · 18.8.2026
MT Newswires · 13.8.2026
GlobeNewswire · 13.8.2026
Benzinga · 13.8.2026
SeekingAlpha · 4.8.2026
Benzinga · 3.8.2026
SeekingAlpha · 1.8.2026
ChartMill · 28.7.2026
Opko Health, Inc. (OPK) currently has a StockIQ AI score of 56/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
OPK currently scores 56/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
OPK's technical score is 79/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Debt/equity: 0.27; Current ratio: 3.97; Price is above the 50-day average.
Based on the real signals StockIQ computed: Operating margin: -19.3% (negative); Net margin: -37.2% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for OPK.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 7 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Rubin Steven D | Tax Withholding in Shares | 24.7.2026 | 53,266 | -53,266 | $1.22 |
| Logal Adam | Tax Withholding in Shares | 24.7.2026 | 53,266 | -53,266 | $1.22 |
| Logal Adam | Tax Withholding in Shares | 24.7.2026 | 563,396 | -53,266 | $1.22 |
| Rubin Steven D | Tax Withholding in Shares | 24.7.2026 | 6,571,966 | -53,266 | $1.22 |
| UPPALURI SUBBARAO V | Grant/Award from Employer | 18.6.2026 | 80,000 | +80,000 | — |
| Yu Alice Lin-Tsing | Grant/Award from Employer | 18.6.2026 | 30,000 | +30,000 | — |
| PFENNIGER RICHARD C JR | Grant/Award from Employer | 18.6.2026 | 60,000 | +60,000 | — |
| MEDEL ROGER MD | Grant/Award from Employer | 18.6.2026 | 30,000 | +30,000 | — |
| Lachman Prem A | Grant/Award from Employer | 18.6.2026 | 30,000 | +30,000 | — |
| PAGANELLI JOHN A | Grant/Award from Employer | 18.6.2026 | 30,000 | +30,000 | — |
| MEDEL ROGER MD | Grant/Award from Employer | 18.6.2026 | 30,000 | +30,000 | — |
| PFENNIGER RICHARD C JR | Grant/Award from Employer | 18.6.2026 | 60,000 | +60,000 | — |
| PAGANELLI JOHN A | Grant/Award from Employer | 18.6.2026 | 30,000 | +30,000 | — |
| UPPALURI SUBBARAO V | Grant/Award from Employer | 18.6.2026 | 80,000 | +80,000 | — |
| Yu Alice Lin-Tsing | Grant/Award from Employer | 18.6.2026 | 30,000 | +30,000 | — |
| Lachman Prem A | Grant/Award from Employer | 18.6.2026 | 30,000 | +30,000 | — |
| PAGANELLI JOHN A | Open Market Purchase | 20.3.2026 | 10,000 | +10,000 | $1.14 |
| PAGANELLI JOHN A | Open Market Purchase | 20.3.2026 | 394,340 | +10,000 | $1.14 |
| UPPALURI SUBBARAO V | Grant/Award from Employer | 18.3.2026 | 50,000 | +50,000 | — |
| UPPALURI SUBBARAO V | Grant/Award from Employer | 18.3.2026 | 50,000 | +50,000 | — |
| FROST PHILLIP MD ET AL | Open Market Purchase | 21.11.2025 | 89,375 | +89,375 | $1.33 |
| FROST PHILLIP MD ET AL | Open Market Purchase | 21.11.2025 | 191,490 | +191,490 | $1.33 |
| FROST PHILLIP MD ET AL | Open Market Purchase | 21.11.2025 | 102,371 | +102,371 | $1.30 |
| FROST PHILLIP MD ET AL | Open Market Purchase | 21.11.2025 | 192,870 | +192,870 | $1.34 |
| FROST PHILLIP MD ET AL | Open Market Purchase | 21.11.2025 | 3,894 | +3,894 | $1.32 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
34,558,372 shares short as of 2026-08-31 · vs. 32,883,700 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
52.5% of trading volume this week was short selling, vs. 53.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology